Zusammenfassung
Die urologische Arbeitsgruppe der EORTC hat in der onkologisch-urologischen Forschung über alle Aspekte des Prostatakarzinoms 12 Jahre Erfahrung. Die Gruppe hat insgesamt 5 Phase-II-Studien beendet, ein sechstes Protokoll ist z. Z. in Arbeit. Drei große randomisierte Studien über nicht vorbehandelte metastasierende Prostatakarzinome wurden abgeschlossen, 4 weitere Protokolle werden zur Zeit bearbeitet. Mehr als 1400 Patienten sind hieran beteiligt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Benson RC, Gill GM, Cummings KB (1983) Randomised double blind crossover trial of Diethyl Stilboestrol (DES) and Estramustine Phosphate (EMCYT). The Stage D Prostatic Cancer. Semin Oncol 10 (Suppl 3): 43–45
Byar DP (1980) A review of the Veterans’ Administration Studies of Cancer of the Prostate: the new results concerning treatment of Stage I and II tumours. In: Pavone Macaluso M, Smith PH, Edsmyr S (eds) Bladder tumours and other topics in urological oncology. Plenum, New York London, pp 471–492
De Voogd HJ, Smith PH, Pavone Macaluso M, de Pauw M, Suciu S, and Members of the European Organization for Research on Treatment of Cancer Urological Group (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135: 303–307
Jones WG, Fossa SD, Denis L, Coninx P, Glashan RW, Akdas A, de Pauw M (1983) An EORTC phase II study of vindesine in advanced prostate cancer. Eur J Cancer 19: 583–588
Jones WG and members of the EORTC Genitourinary Cancer Cooperative Group (1984) EORTC Phase II Chemotherapy studies in prostate cancer. In: Denis L, Murphy GP, Prout GR, Schröder FH (eds) Controlled clinical trials in urologic oncology. Raven, New York, pp 181–185
Jones WG, Bono AV, Verbaeys A, de Pauw M, Sylvester R, and members of the EORTC Genitourinary Tract Cancer Cooperative Group (1986a) Can the primary tumour be used as the sole parameter for response in phase II chemotherapy studies in metastatic prostate cancer? An EORTC Genitourinary Group report. World J Urol 4: 176–181
Jones WG, Fossa SD, Bono AV, Croles JJ, Stoter G, de Pauw M, Slyvester R, and members of the EORTC Genitourinary Tract Cancer Cooperative Group (1986b) Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study. World J Urol 4: 182–185
Jones WG, Fossa SD, Bono AV, Klijn JMG, de Pauw M, Sylvester R (1987) European Organization for Research and Treatment of Cancer ( EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer Treat Rep 71: 1317–1318
Pavone Macaluso M, Lund F, Mulder JH, Smith PH, de Pauw M, Sylvester R, and the EORTC Urological Group (1980) EORTC protocols in prostatic cancer. Scand J Urol Nephrol (Suppl) 55: 163–168
Pavone Macaluso M, de Pauw M, Suciu S, Sylvester R, de Voogd HJ, Lardennois B, Nasta A, Zolfanelli R, Barasoldo E, and the EORTC Urological Group (1982) Medroxyprogesterone acetate, diethylstilboestrol and cyproterone acetate in the treatment of the prostatic cancer. Interim report of a prospective study of the European Organization for Research on the Treatment of Cancer (EORTC) Genito-urinary Tract Cooperative Group. Excerpta Medica International Series, pp 436–444
Pavone Macaluso M and the EORTC Urological Group (1983) Medroxyprogesterone acetate in the treatment of prostatic cancer: preliminary results of EORTC trial 30761 comparing MPA with Stilbestrol and with Cyproterone Acetate. In: Campio L, Robustelli Della Cua G, Taylor RW (eds) Role of medroxyprogesterone in endocrine related tumors. Raven, New York, pp 183–190
Pavone Macaluso M, de Voogd HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R (1986) Diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomised phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136: 624–631
Poyet P, Labrie F (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 42: 283–288
Robinson MRG, Hetherington J (1986) The EORTC studies: is there an optimal endocrine management for M1 prostatic cancer? World J Urol 4: 171–175
Schröder FH, and the EORTC Urological Group (1984) Treatment of prostatic cancer: EORTC experience–preliminary results of prostatic carcinoma trials. Prostate 5: 193–198
Smith PH (1980) Medical management of prostatic cancer. Some current questions. Eur Urol 6: 65–68
Smith PH, Suciu S, Robinson MRG, Richards B, Bastable JRG, Glashan RW, Bouffioux C, Lardennois B, Williams RE, de Pauw M, Sylvester R (1986) A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J Urol 136: 619–623
Author information
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schröder, F.H., die urologische Arbeitsgruppe der EORTC. (1990). Prospektive Studien von metastasierenden Prostatakarzinomen: 12 Jahre Erfahrung der urologischen Arbeitsgruppe der EORTC. In: Frohmüller, H.G.W., Wirth, M.P. (eds) Behandlung des fortgeschrittenen Prostatakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84064-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-84064-7_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-52076-4
Online ISBN: 978-3-642-84064-7
eBook Packages: Springer Book Archive